促性腺激素释放激素激动剂在多囊卵巢综合征中的应用。对骨量的影响。

Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.

作者信息

Lupoli G, Di Carlo C, Nuzzo V, Vitale G, Russo D, Palomba S, Nappi C

机构信息

Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Facoltà di Medicina e Chirurgia, Università Federico II, Napoli, Italy.

出版信息

J Endocrinol Invest. 1997 Sep;20(8):493-6. doi: 10.1007/BF03348007.

DOI:10.1007/BF03348007

PMID:9364254

Abstract

Women with amenorrhea and polycystic ovaries (PCO) seem to present a relative degree of protection against bone loss caused by hypoestrogenism. We treated 20 patients affected by polycystic ovary syndrome (PCOS) with a gonadotropin-releasing hormone agonist (GnRH-a) for 6 months. After treatment mean bone mineral density (BMD) significantly decreased. We concluded that patients with PCOS have to be considered at risk of developing osteopenia when treated with GnRH-a. The relative protection against osteoporosis, that is present in amenorrheic patients with PCO, might be attributed to the characteristics of amenorrhea in these patients.

摘要

患有闭经和多囊卵巢（PCO）的女性似乎对低雌激素血症引起的骨质流失具有一定程度的保护作用。我们用促性腺激素释放激素激动剂（GnRH-a）治疗了20例多囊卵巢综合征（PCOS）患者，疗程为6个月。治疗后平均骨矿物质密度（BMD）显著下降。我们得出结论，PCOS患者在接受GnRH-a治疗时必须被视为有发生骨质减少的风险。闭经的PCO患者所具有的对骨质疏松症的相对保护作用，可能归因于这些患者闭经的特点。